DK474189D0 - Antistof - Google Patents

Antistof

Info

Publication number
DK474189D0
DK474189D0 DK474189A DK474189A DK474189D0 DK 474189 D0 DK474189 D0 DK 474189D0 DK 474189 A DK474189 A DK 474189A DK 474189 A DK474189 A DK 474189A DK 474189 D0 DK474189 D0 DK 474189D0
Authority
DK
Denmark
Prior art keywords
antibody
Prior art date
Application number
DK474189A
Other languages
English (en)
Other versions
DK474189A (da
Inventor
Susumu Iwasa
Tomofumi Kurokawa
Yukio Toyoda
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of DK474189D0 publication Critical patent/DK474189D0/da
Publication of DK474189A publication Critical patent/DK474189A/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46Hybrid immunoglobulins
    • C07K16/468Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6815Enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • A61K47/6879Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the immunoglobulin having two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
DK474189A 1988-09-27 1989-09-26 Monoklonalt antistof DK474189A (da)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP24354488 1988-09-27
JP30192588 1988-11-28
JP6294089 1989-03-14
JP16487389 1989-06-27
JP20893689A JP3177776B2 (ja) 1988-09-27 1989-08-11 ハイブリッドモノクローナル抗体,抗体産生ポリドーマおよび抗体含有薬剤

Publications (2)

Publication Number Publication Date
DK474189D0 true DK474189D0 (da) 1989-09-26
DK474189A DK474189A (da) 1990-03-28

Family

ID=27523741

Family Applications (1)

Application Number Title Priority Date Filing Date
DK474189A DK474189A (da) 1988-09-27 1989-09-26 Monoklonalt antistof

Country Status (15)

Country Link
US (1) US5506135A (da)
EP (1) EP0363712B1 (da)
JP (1) JP3177776B2 (da)
KR (1) KR900004351A (da)
CN (1) CN1041783A (da)
AR (1) AR242832A1 (da)
AT (1) ATE140930T1 (da)
AU (1) AU628857B2 (da)
DE (1) DE68926899T2 (da)
DK (1) DK474189A (da)
FI (1) FI894551A (da)
HU (1) HUT55445A (da)
IL (1) IL91649A (da)
NO (1) NO893818L (da)
PT (1) PT91808B (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030068322A1 (en) * 1988-04-18 2003-04-10 Immunomedics, Inc. Methods of antibody-directed enzyme-prodrug therapy
TW212184B (da) * 1990-04-02 1993-09-01 Takeda Pharm Industry Co Ltd
JPH0576385A (ja) * 1990-12-18 1993-03-30 Takeda Chem Ind Ltd キメラ抗体およびその用途
CA2108451A1 (en) * 1991-04-26 1992-10-27 Beverley J. Randle Novel antibodies, and methods for their use
WO2015053381A1 (ja) * 2013-10-10 2015-04-16 幸成 加藤 抗ポドプラニン抗体
JP7204132B2 (ja) * 2017-05-02 2023-01-16 国立研究開発法人国立がん研究センター プラスミンにより切断可能な抗不溶性フィブリン抗体と薬物とのコンジュゲート

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474893A (en) * 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4714681A (en) * 1981-07-01 1987-12-22 The Board Of Reagents, The University Of Texas System Cancer Center Quadroma cells and trioma cells and methods for the production of same
CA1213229A (en) * 1982-04-12 1986-10-28 Gary S. David Antibodies having dual specificities, their preparation and uses therefor
WO1987006240A1 (en) * 1986-04-14 1987-10-22 The General Hospital Corporation Heterobifunctional antibodies and method of use
US4916070A (en) * 1986-04-14 1990-04-10 The General Hospital Corporation Fibrin-specific antibodies and method of screening for the antibodies

Also Published As

Publication number Publication date
DE68926899D1 (de) 1996-09-05
FI894551A0 (fi) 1989-09-26
AR242832A1 (es) 1993-05-31
IL91649A (en) 1994-10-21
NO893818D0 (no) 1989-09-26
EP0363712A2 (en) 1990-04-18
DK474189A (da) 1990-03-28
PT91808B (pt) 1995-05-31
ATE140930T1 (de) 1996-08-15
IL91649A0 (en) 1990-04-29
HUT55445A (en) 1991-05-28
DE68926899T2 (de) 1997-01-02
PT91808A (pt) 1990-03-30
CN1041783A (zh) 1990-05-02
EP0363712B1 (en) 1996-07-31
KR900004351A (ko) 1990-04-12
AU628857B2 (en) 1992-09-24
NO893818L (no) 1990-03-28
JPH03103175A (ja) 1991-04-30
US5506135A (en) 1996-04-09
JP3177776B2 (ja) 2001-06-18
EP0363712A3 (en) 1990-08-16
FI894551A (fi) 1990-03-28
AU4174789A (en) 1990-04-05

Similar Documents

Publication Publication Date Title
DK666389A (da) Monoklonalt antistof
ATA901789A (de) Somatostatinpeptid
BR8806093A (pt) Trepano
ATA900689A (de) Calcitoninpeptide
DE3879452D1 (de) Chimaere antikoerper.
DK532589D0 (da) Referenceelektrode
DK190889A (da) Antigen
NO177311C (no) Anti-fucosylceramid monoklonalt antistoff
BR8902098A (pt) Eletrolisador
BR8906898A (pt) Jamela
DK474189D0 (da) Antistof
DK413389D0 (da) Monoklonale antistoffer
DE68926367D1 (de) Hydroxymethylcyclobutylpurine
DK554986D0 (da) Antistof
KR890023207U (ko) 관계수
DD277186A3 (de) Waelzlagerseparator
DK594189A (da) Anti-hcg-antistoffer
DK220688D0 (da) Monoklonalt antistof
ATE87031T1 (de) Chimaere antikoerper.
BR6801964U (pt) Fecho
BR6800108U (pt) Supercross
BR6800600U (pt) Hidro-serra
BR6800871U (pt) Giro-arte
BR6800913U (pt) Trailer-sanitarios publico
BR6801036U (pt) Rechaud

Legal Events

Date Code Title Description
AHB Application shelved due to non-payment